Objective: To evaluate the materno-fetal outcome of high-risk women using placental growth factor (PlGF).
Methods: This prospective cohort study was performed at a tertiary care hospital from September 2019 to April 2022. Women having clinically major or minor high risk factors of pre-eclampsia were included after consent.